Traws Pharma Inc - Company Profile
Powered by 
All the sales intelligence you need on Traws Pharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Traws Pharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Traws Pharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Traws Pharma Inc (Traws Pharma), formerly Onconova Therapeutics Inc, is a clinical stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases. It is also developing narazaciclib a multi-kinase CDK4-plus inhibitor for refractory endometrial and metastatic breast cancer. The company focuses on advancing investigational antiviral agents with potent activity against difficult-to-treat or resistant virus strains. Traws Pharma's major products include tivoxavir marboxil, an oral small molecule for bird flu and seasonal influenza, and ratutrelvir, a COVID-19 treatment. The company conduct its manufacturing activities under individual purchase orders with third-party contract manufacturers. Traws Pharma is headquartered in Newtown Square, New Jersey, the US.
Headquarters
United States of America
Address
12 Penns Trail, Newtown Square, Pennsylvania, 18940
Website
www.trawspharma.com
Telephone
1 267 7593680
No of Employees
4
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TRAW (NASD)
Revenue (2024)
$2.8M
1134.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
105.5%
(2024 vs 2023)
Market Cap*
$8.3M
Net Profit Margin (2024)
XYZ
100.5%
(2024 vs 2023)
* As of and is in US$
Traws Pharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| TRX01 (Ratutrelvir): SAR-CoV-2 Virus |
| Tivoxavir Marboxil: Bird Flu and Seasonal Influenza |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In February, the company developed ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor. |
| 2025 | Plans/Strategy | In September, the company announced its plans to acquire Certain Assets from Viriom Inc. for US$2.4 million. |
| 2024 | Acquisitions/Mergers/Takeovers | In April, the company acquired Trawsfynydd Therapeutics Inc, a biotechnology firm. |
Competitor Comparison
| Key Parameters | Traws Pharma Inc | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Switzerland |
| City | Newtown Square | Indianapolis | Rahway | New York City | Basel |
| State/Province | Pennsylvania | Indiana | New Jersey | New York | Basel-Stadt |
| No. of Employees | 4 | 50,605 | 75,000 | 75,000 | 75,267 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jack E. Stover | Chairman | Executive Board | 2025 | 73 |
| Iain Dukes | Chief Executive Officer; Director | Executive Board | 2025 | 67 |
| Nikolay Savchuk | Director; Chief Operating Officer | Executive Board | 2024 | 74 |
| Charles Parker | Chief Financial Officer | Senior Management | 2025 | 46 |
| C. David Pauza | Chief Science Officer-Virology | Senior Management | 2024 | 71 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer